Chemotherapy-Induced Cardiotoxicity

Shaikh, Amir Y.; Shih, Jeffrey

doi:10.1007/s11897-012-0083-y

Cited by 64 publications

(45 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Binding of Doxorubicin with the cell results in the production of active oxygen species, especially hydroxyl radicals. This leads to a decline of mitochondrial oxidative phosphorylation [1,6,7]. Administering Doxorubicin via intravenous injections leads to several side effects associated with chemotherapeutic drugs.…”

Section: Introductionmentioning

confidence: 99%

“…The induced cardiotoxicity can be acute, usually manifesting within the first 2–3 days of administration. Doxorubicin cardiomyopathy once developed has poor prognosis and is frequently fatal, affecting nearly 11% of all patients [7,8]. In order to overcome systemic toxicity caused by drug administration, Doxorubicin can be administered instead as a molecular theranostic agent with targeted delivery to Scavenger receptors type B1 (SR-B1) overexpressed in tumors; by encapsulation in reconstituted high density lipoprotein (rHDL) nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fluorescence properties of doxorubicin in PBS buffer and PVA films

Shah

Chandra

Kaur

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

109

View full text Add to dashboard Cite

We studied steady-state and time-resolved fluorescence properties of an anticancer drug Doxorubicin in a saline buffer and poly-vinyl alcohol (PVA) film. Absorption of Doxorubicin, located at blue-green spectral region, allows a convenient excitation with visible light emitting diodes or laser diodes. Emission of Doxorubicin with maximum near 600nm can be easily detected with photomultipliers and CCD cameras. Both, absorption and fluorescence spectra in polymeric matrix show more pronounced vibronic structures than in solution. Also, the steady-state anisotropy in the polymer film is significantly higher than in the saline solution. In PVA film the fluorescence anisotropy is about 0.30 whereas in the saline buffer only 0.07. Quantum efficiencies of Doxorubicin were compared to a known standard Rhodamine 101 which has fluorescence emission in a similar spectral region. The quantum yield of Doxorubicin in PVA film is more than 10% and about twice higher than in the saline solution. Similarly, the lifetime of doxorubicin in PVA film is about 2 ns whereas in the saline solution only about 1 ns. The fluorescence anisotropy decays show that Doxorubicin molecules are freely rotating in the saline buffer with a correlation time of about 290 ps, and are almost completely immobilized in the PVA film. The spectroscopic investigations presented in this manuscript are important, as they provide answers to changes in molecular properties of Doxorubicin depending changes in the local environment, which is useful when synthesizing nano-particles for Doxorubicin entrapment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fluorescence properties of doxorubicin in PBS buffer and PVA films

Shah

Chandra

Kaur

et al. 2017

Journal of Photochemistry and Photobiology B: Biology

109

View full text Add to dashboard Cite

show abstract

“…In addition, targeting the ubiquitin‐proteasome pathway is an emerging concept in cancer therapy based on the hypothesis that many proteins in the proteasome are implicated in the regulation of important processes of carcinogenesis and cancer cell survival . Several proteasome‐targeting inhibitors (e.g., bortezomib, carfilzomib) have been introduced in the clinic. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma reported that bortezomib‐based treatment was associated with a low incidence of cardiac events .…”

Section: Fda‐approved Mtts For Oncologymentioning

confidence: 99%

Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

Zheng

Kros

2017

Medicinal Research Reviews

View full text Add to dashboard Cite

To date, five cancer treatment modalities have been defined. The three traditional modalities of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two modern modalities include molecularly targeted therapy (the fourth modality) and immunotherapy (the fifth modality). The cardiotoxicity associated with conventional chemotherapy and radiotherapy is well known. Similar adverse cardiac events are resurging with the fourth modality. Aside from the conventional and newer targeted agents, even the most newly developed, immune‐based therapeutic modalities of anticancer treatment (the fifth modality), e.g., immune checkpoint inhibitors and chimeric antigen receptor (CAR) T‐cell therapy, have unfortunately led to potentially lethal cardiotoxicity in patients. Cardiac complications represent unresolved and potentially life‐threatening conditions in cancer survivors, while effective clinical management remains quite challenging. As a consequence, morbidity and mortality related to cardiac complications now threaten to offset some favorable benefits of modern cancer treatments in cancer‐related survival, regardless of the oncologic prognosis. This review focuses on identifying critical research‐practice gaps, addressing real‐world challenges and pinpointing real‐time insights in general terms under the context of clinical cardiotoxicity induced by the fourth and fifth modalities of cancer treatment. The information ranges from basic science to clinical management in the field of cardio‐oncology and crosses the interface between oncology and onco‐pharmacology. The complexity of the ongoing clinical problem is addressed at different levels. A better understanding of these research‐practice gaps may advance research initiatives on the development of mechanism‐based diagnoses and treatments for the effective clinical management of cardiotoxicity.

show abstract

“…Modern therapeutic approaches against advanced stage solid tumors include chemotherapy or radiotherapy, which are found to be very much detrimental to the host due to their non-specific action. [1][2][3] Moreover, most of the advanced stage solid tumors often metastasize from their site of origin to distant organs, thereby adding further complication to their treatment. 4 In this regard, immunotherapeutic approaches may be helpful due to their specific action on cancer cells.…”

Section: Introductionmentioning

confidence: 99%